Xilio Therapeutics (XLO) Cash from Financing Activities (2020 - 2026)

Xilio Therapeutics has disclosed Cash from Financing Activities across 7 years of filings, most recently posting $35.7 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $35.7 million, up 638.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $118.6 million (up 258.74% YoY), and the FY2025 annual result was $87.8 million, up 200.64% from the prior year.
• Cash from Financing Activities came in at $35.7 million for Q1 2026 at Xilio Therapeutics, roughly flat from $35.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $47.4 million in Q2 2025 to a low of -$2.2 million in Q3 2023.
• The 5-year median for Cash from Financing Activities is -$5000.0 (2022), against an average of $8.6 million.
• Across the five-year window, Cash from Financing Activities slumped 33660.0% in 2023 and jumped 2120.46% in 2024, its largest moves.
• Xilio Therapeutics' Cash from Financing Activities stood at -$21000.0 in 2022, then slumped by 7680.95% to -$1.6 million in 2023, then jumped by 601.96% to $8.2 million in 2024, then soared by 337.28% to $35.9 million in 2025, then decreased by 0.44% to $35.7 million in 2026.
• The last three Cash from Financing Activities figures came in at $35.7 million (Q1 2026), $35.9 million (Q4 2025), and -$285000.0 (Q3 2025), per Business Quant data.